AzarGen Biotechnologies Overview

  • Founded
  • 2003

Founded
  • Status
  • Private

  • Employees
  • 5

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $3.1M

  • Investors
  • 2

AzarGen Biotechnologies General Information

Description

Developer of human therapeutic proteins designed to increase the survivability of premature-born infants. The company's human therapeutic proteins are made using advanced plant-based genetic engineering and synthetic biology techniques and it also offers a plant-based expression technology that comprises optimal combinations of novel synthetic promoters, combined with enhancer and purification components, enabling medical professionals to offer drugs with superior clinical efficacy at low cost that can significantly improve the health status of citizens.

Contact Information

Website
www.azargen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
  • Launchlab Hammandshand Road
  • Stellenbosch
  • Cape Town, 7600
  • South Africa
+27 021 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AzarGen Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) 07-Jan-2016 $3.1M 00.00 Completed Generating Revenue
1. Grant Completed Startup
To view AzarGen Biotechnologies’s complete valuation and funding history, request access »

AzarGen Biotechnologies Patents

AzarGen Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015262984-A1 Synthetic promoter construct for transgene expression Abandoned 19-May-2014 00000000000
CA-2947805-A1 Synthetic promoters for transgene expression in plants Abandoned 19-May-2014 00000000000
EP-3146053-A1 Synthetic promoter construct for transgene expression Withdrawn 19-May-2014 00000000000
US-9670497-B2 Synthetic promoter construct for transgene expression Active 19-May-2014 00000000000 0
US-20150329869-A1 Synthetic promoter construct for transgene expression Granted 19-May-2014 C12N15/8216 0
To view AzarGen Biotechnologies’s complete patent history, request access »

AzarGen Biotechnologies Executive Team (2)

Name Title Board Seat Contact Info
Mauritz Venter Ph.D Co-Founder & Chief Executive Officer
Cobus Zwiegelaar Ph.D Co-Founder, Chief Operating Officer & Director
To view AzarGen Biotechnologies’s complete executive team members history, request access »

AzarGen Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AzarGen Biotechnologies Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Industrial Development Corporation of South Africa Corporation Minority 000 0000 000000 0
South African Government Government 000 0000 000000 0
To view AzarGen Biotechnologies’s complete investors history, request access »